The Opportunity for ALLR Investors
Los Angeles, Oct. 17, 2024 — Glancy Prongay & Murray LLP (“GPM”) announces that investors with substantial losses have an opportunity to lead the securities fraud class action lawsuit against Allarity Therapeutics, Inc. (“Allarity” or the “Company”) ALLR.
Class Period: May 17, 2022 – July 19, 2024
Lead Plaintiff Deadline: November 12, 2024
If you wish to serve as the lead plaintiff of the Allarity lawsuit, you can submit your contact information at www.glancylaw.com/cases/Allarity-Therapeutics-Inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.
The complaint alleges that, throughout the Class Period, Defendants failed to disclose to investors that they had overstated the Dovitinib NDA’s continued regulatory prospects and engaged in illegal conduct. This misconduct exposed the Company to an increased risk of regulatory scrutiny and enforcement action.
Follow us for updates on LinkedIn, Twitter, or Facebook.
To be a member of the class action, you need not take any action at this time. If you wish to learn more about this class action, please contact Charles Linehan, Esquire, of GPM.
This press release may be considered Attorney Advertising in some jurisdictions under applicable law.
Contacts: Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com
View original content: Original Source
Market News and Data brought to you by Benzinga APIs